Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Public ClinicalTrials.gov record NCT00440193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Study identification
- NCT ID
- NCT00440193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 3,449 participants
Conditions and interventions
Conditions
Interventions
- Rivaroxaban (Xarelto, BAY59-7939) Drug
- Enoxaparin followed by VKA Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2007
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2010
- Last update posted
- Feb 26, 2014
2007 – 2010
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Redlands | California | 92373 | — |
| Not listed | Bay Pines | Florida | 33744 | — |
| Not listed | Miami | Florida | 33136-1096 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Idaho Falls | Idaho | 83404 | — |
| Not listed | Covington | Louisiana | 70433 | — |
| Not listed | Baltimore | Maryland | 21215 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Albuquerque | New Mexico | 87108-4763 | — |
| Not listed | Chapel Hill | North Carolina | 27599-7035 | — |
| Not listed | Greensboro | North Carolina | 27401 | — |
| Not listed | Greensboro | North Carolina | 27403 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Camp Hill | Pennsylvania | 17011 | — |
| Not listed | Pittsburgh | Pennsylvania | 15224 | — |
| Not listed | Corsicana | Texas | 75110 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Murray | Utah | 84157 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Fredericksburg | Virginia | 22401 | — |
| Not listed | Spokane | Washington | 99204 | — |
| Not listed | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 301 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00440193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00440193 live on ClinicalTrials.gov.